Mallinckrodt (NYSE:MNK) updated its FY earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of $6.00-6.50 for the period, compared to the Thomson Reuters consensus estimate of $7.14. The company issued revenue guidance of +3-6% to ~$.
MNK has been the subject of a number of research analyst reports. Oppenheimer reissued a hold rating on shares of Mallinckrodt in a report on Tuesday. Cantor Fitzgerald set a $42.00 price target on Mallinckrodt and gave the stock a buy rating in a report on Tuesday. Barclays cut Mallinckrodt from an equal weight rating to an underweight rating and lowered their price target for the stock from $23.00 to $20.00 in a report on Friday, February 2nd. ValuEngine cut Mallinckrodt from a buy rating to a hold rating in a report on Friday, February 2nd. Finally, Zacks Investment Research raised Mallinckrodt from a strong sell rating to a hold rating in a report on Tuesday, January 9th. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating and seven have given a buy rating to the stock. Mallinckrodt presently has an average rating of Hold and a consensus price target of $42.64.
Shares of Mallinckrodt (MNK) traded down $1.79 on Wednesday, reaching $16.87. The company’s stock had a trading volume of 6,309,481 shares, compared to its average volume of 3,564,979. Mallinckrodt has a fifty-two week low of $15.27 and a fifty-two week high of $53.60. The company has a current ratio of 1.38, a quick ratio of 1.05 and a debt-to-equity ratio of 1.08. The firm has a market cap of $1,538.13, a PE ratio of 5.04, a PEG ratio of 0.30 and a beta of 1.04.
COPYRIGHT VIOLATION NOTICE: This news story was posted by Ticker Report and is owned by of Ticker Report. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright & trademark laws. The correct version of this news story can be viewed at https://www.tickerreport.com/banking-finance/3228101/mallinckrodt-mnk-releases-fy-earnings-guidance.html.
Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs.
Receive News & Ratings for Mallinckrodt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt and related companies with MarketBeat.com's FREE daily email newsletter.